Format

Send to

Choose Destination
Neurology. 2003 Nov 11;61(9):1279-81.

A randomized trial of botulinum toxin A for treatment of drooling.

Author information

1
Department of Neurology, Medical Faculty of the Charité, Humboldt University, Berlin, Germany.

Abstract

The authors compared the efficacy of three different doses (18.75, 37.5, and 75 MU per parotid gland) of botulinum toxin A (BTX-A; Dysport, Ipsen Pharma, Germany) injections vs vehicle in patients with sialorrhea (n = 32) using a single-center, prospective, double-blind, placebo-controlled dose-finding study. The primary endpoint was achieved with 75 MU BTX-A without treatment-related adverse events, suggesting BTX-A is a safe and effective treatment for patients with sialorrhea.

PMID:
14610139
DOI:
10.1212/wnl.61.9.1279
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center